All In Biotech

Drug Trial Radar · NCT07932691

Phase I Trial of Subcutaneous VDJ010 In Healthy Subjects and Patients With Ulcerative Colitis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of VDJ010 for Subcutaneous Injection in Healthy Chinese Subjects and Patients With Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Aug 9, 2024

Primary completion

Nov 30, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Beijing VDJBio Co., LTD.Industry
Sponsor type
Industry
First posted
Nov 12, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study adopted a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose design, using recombinant human IL-2 fusion protein (VDJ010) administered subcutaneously to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy Chinese subjects and patients with ulcerative colitis.

Conditions

  • Ulcerative Colitis (UC)

Interventions

  • Recombinant Human Interleukin-2 Fusion Protein with Human Serum Albumin (VDJ010)Drug

    VDJ010 is a recombinant fusion protein consisting of human interleukin-2 (IL-2) genetically fused to human serum albumin (HSA), produced using Chinese hamster ovary (CHO) cells through DNA recombinant technology. The fusion protein selectively binds to the high-affinity IL-2 receptor (IL-2Rαβγ) constitutively expressed on regulatory T cells (Treg), thereby promoting Treg expansion and restoring immune tolerance in autoimmune diseases such as ulcerative colitis. The HSA moiety extends the plasma half-life of IL-2 to enable less frequent subcutaneous dosing.

  • PlaceboDrug

    This is a matching placebo formulation containing no active pharmaceutical ingredient (API). The placebo is manufactured to be identical in appearance, color, shape, size, and packaging to the investigational product VDJ010 to maintain the integrity of the double-blind design. It is utilized solely as a control intervention for the purpose of this randomized, double-blind, placebo-controlled Phase I clinical trial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerabilityTime frame: First dose up to last follow-up visit (Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration)
  2. Peak Serum Concentration (Cmax)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration.
  3. Time to Peak Concentration (Tmax)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration.
  4. Area Under the Serum Concentration-Time Curve from Time Zero to Last Quantifiable Concentration (AUC0-t)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  5. Area Under the Serum Concentration-Time Curve from Time Zero to Infinity (AUC0-∞)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  6. Terminal Elimination Rate Constant (λz)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  7. Terminal Elimination Half-Life (t1/2z)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  8. Clearance (CLz)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  9. Trough Concentration at Steady State (Cmin,ss / Ctrough,ss)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  10. Area Under the Curve over One Dosing Interval at Steady State (AUC0-τ,ss)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  11. Average Concentration at Steady State (Cav,ss)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  12. Degree of Fluctuation (DF)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  13. SwingTime frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  14. Apparent Volume of Distribution at Steady State (Vss/F)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  15. Apparent Clearance at Steady State (CLss/F)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  16. Percentage of AUC Extrapolated to Infinity (AUC_%Extrap)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  17. Mean Residence Time to Infinity (MRT0-∞)Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  18. Accumulation Ratio Based on Cmax (Ra(Cmax))Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  19. Accumulation Ratio Based on AUC (Ra(AUC))Time frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration
  20. ImmunogenicityTime frame: Healthy Subjects: 43 days after administration; UC Patients: 57 days after administration

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Not yet recruiting

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Xiamen Hospital of Traditional Chinese Medicine

    Xiamen, Fujian, China · Not yet recruiting

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Not yet recruiting

  • The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Not yet recruiting

  • The First Hospital of Shanxi Medical University

    Taiyuan, Shanxi, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.